News

News

Treating the Seeds of Cancer

athernal bio is developing the first immunotherapies for high-risk clonal haematopoiesis — addressing blood cancer precursor conditions with the aim of stopping cancer before it starts through early and proactive therapeutic intervention.

MISSION

To design, develop and deliver the first targeted immunotherapies for high-risk blood cancer precursor conditions

UNMET NEED

Clonal haematopoiesis: a silent but widespread risk

Clonal haematopoiesis (CH) occurs when blood stem cells acquire mutations that give them a growth advantage. These altered stem cells expand over time, increasing the risk of blood cancers such as acute myeloid leukaemia (AML) and contributing to cardiovascular and other age-related diseases. Despite its prevalence and impact, there are currently no approved therapies for CH.

Patient receiving chemotherapy treatment

Genetic predispositions

People over 60

Cancer survivors

Clonal Haematopoiesis

Cancer Precursor Disease

Accelerates AML

Illustration of clonal haematopoiesis cells

Genetic predispositions

People over 60

Cancer survivors

Clonal Haematopoiesis

Cancer Precursor Disease

Accelerates AML

Illustration of clonal haematopoiesis cells

Genetic predispositions

People over 60

Cancer survivors

Clonal Haematopoiesis

Cancer Precursor Disease

Accelerates AML

Illustration of clonal haematopoiesis cells
OUR APPROACH

A new therapeutic category for oncology

We are building immunotherapies that train the immune system to detect and eliminate CH-affected stem cells, addressing the earliest step in the development of blood cancers.

Frontline immunotherapy

Taking immunotherapy to the earliest stage of disease, before blood cancers emerge.

Precision by Design

Precision by Design

Targeted to maximise effectiveness while minimising risk.

Targeted to maximise effectiveness while minimising risk.

A LNP therapy with a vial in the background

Accelerated clinical strategy

Accelerated clinical strategy

Initially focusing on orphan indications with clear regulatory pathways to bring therapies to patients faster.

Initially focusing on orphan indications with clear regulatory pathways to bring therapies to patients faster.

Transformative opportunity

Transformative opportunity

Delivering the first treatment option for a condition affecting millions and linked to multiple diseases.

Delivering the first treatment option for a condition affecting millions and linked to multiple diseases.

PIPELINE

Lead Programmes

athernal bio is developing targeted immunotherapies to treat clonal haematopoiesis before cancers become established.

Programme
Discovery

Discovery

Discovery

Preclinical

Preclinical

Preclinical

IND

IND

IND

Phase I

Phase I

Phase I

ath-001

Rare blood disorders with accelerated CH and AML risk

ath-001

Rare blood disorders with accelerated CH and AML risk

ath-002

Therapy-induced CH

Following chemotherapy or radiotherapy in cancer survivors

ath-002

Therapy-induced CH

Following chemotherapy or radiotherapy in cancer survivors

SCIENCE

Targeting the First Step in Cancer Evolution

Clonal haematopoiesis (CH) arises when blood stem cells, also called haematopoietic stem cells (HSCs), acquire mutations that give them a survival and growth advantage. Over time, these altered stem cells expand, reshaping the blood system and significantly increasing the risk of blood cancers and other diseases.

E

x

p

l

o

r

e

M

o

r

e

Infographic showing the four stages of clonal hematopoiesis

Healthy HSCs

Normally, haematopoietic stem cells produce a balanced mix of healthy blood cells.

Mutated HSCs

Some acquire mutations that give them an advantage.

Clonal Expansion

These altered stem cells grow faster and outcompete normal cells.

Disease Risk

As the altered stem cells expand, they drive inflammation and raise the risk of:

SCIENCE

Targeting the First Step in Cancer Evolution

Clonal haematopoiesis (CH) arises when blood stem cells, also called haematopoietic stem cells (HSCs), acquire mutations that give them a survival and growth advantage. Over time, these altered stem cells expand, reshaping the blood system and significantly increasing the risk of blood cancers and other diseases.

Healthy HSCs

Normally, haematopoietic stem cells produce a balanced mix of healthy blood cells.

Mutated HSCs

Some acquire mutations that give them an advantage.

Clonal Expansion

These altered stem cells grow faster and outcompete normal cells.

Disease Risk

As the altered stem cells expand, they drive inflammation and raise the risk of:

Infographic showing the four stages of clonal hematopoiesis
SCIENCE

Targeting the First Step in Cancer Evolution

Clonal haematopoiesis (CH) arises when blood stem cells, also called haematopoietic stem cells (HSCs), acquire mutations that give them a survival and growth advantage. Over time, these altered stem cells expand, reshaping the blood system and significantly increasing the risk of blood cancers and other diseases.

Healthy HSCs

Normally, haematopoietic stem cells produce a balanced mix of healthy blood cells.

Mutated HSCs

Some acquire mutations that give them an advantage.

Clonal Expansion

These altered stem cells grow faster and outcompete normal cells.

Disease Risk

As the altered stem cells expand, they drive inflammation and raise the risk of:

Infographic showing the four stages of clonal hematopoiesis
EXPERTS

Meet our team

Clinicians, scientists and drug developers with deep experience in haematology, immunology and translational medicine.

Portrait of Nirupa Desai
Portrait of Nirupa Desai

Nirupa Desai, MD, MRCP, PhD, FRCPath

Founder & Chief Scientific Officer
Portrait of Caroline Haegeman
Portrait of Caroline Haegeman

Caroline Haegeman, PhD

Founder & Chief Operating Officer
Portrait of Zahid Bashir
Portrait of Zahid Bashir

Zahid Bashir, MD, MFPM, MS

Chief Medical Officer
Portrait of Laurens van Pinxteren
Portrait of Laurens van Pinxteren

Laurens van Pinxteren, PhD, MBA

Head of CMC

Pablo Becker, PhD

Senior Director of Immunology
Portrait of Louise Hosie

Louise Hosie, PhD

Immunology
Portrait of Colin Freund

Colin Freund

Chair
Portrait of Jonathan Hay

Jonathan Hay, PhD

Board Member
Portrait of Peter Smith

Peter Smith, PhD

Board Member

Martin Olin

Board Member

Our Advisors

Portrait of Prof. Alan Warren

Prof. Alan Warren

Professor of Haematology, University of Cambridge
Portrait of Prof. KJ Patel

Prof. KJ Patel

Chief Scientist for CRUK, Director of the MRC Weatherall Institute of Molecular Medicine, University of Oxford
Portrait of Dr. George Vassiliou

Prof. George Vassiliou

Professor of Haematological Medicine, University of Cambridge
Portrait of Dr. Jessica B. Flechtner

Dr. Jessica B. Flechtner

Principal and CEO of Flechtner Biotechnologies. Former CSO of Genocea Biosciences and co-founder, CSO/COO of DoriNano
Portrait of Dr. Shinu John

Dr. Shinu John

Ex-Head of Immunology, ReNAgade Therapeutics; Ex-Moderna
Portrait of Prof. David Kent

Prof. David Kent

Professor of Stem Cell Biology, Centre for Blood Research, University of York.
Portrait of Dr. Juan Li

Dr. Juan Li

Department of Haematology, University of Cambridge

Christine Swenson, PhD

Regulatory Advisor
A mutated hematopoietic stem cells
A healthy hematopoietic stem cells
An early mutated hematopoietic stem cells
INVESTORS

Interested in supporting our mission?

Reach out to explore funding opportunities.

COLLABORATORS

Let's discuss how we can work together to accelerate breakthroughs.